Anticoagulation: Safe prescribing, dispensing and administration of oral and parenteral anticoagulants

**Date**
April 2018

**Version**
4

**Purpose**
To manage the inherent risks to patients from the use of anticoagulant therapy when prescribing, administering or dispensing these medicines by ensuring safe systems of working and clear responsibilities. This policy meets or exceeds the requirements of NPSA safer practice notice no.18 – Actions to make anticoagulant therapy safer.

**Who should read this document?**
All prescribers and nursing staff. All pharmacists and other pharmacy staff involved in dispensing or in advising patients about their medicines.

**Key messages**
Anticoagulants are associated with a high risk of patient harm if therapy is not managed appropriately. All those involved with prescribing, administering or dispensing anticoagulants or in prescribing medicines for patients already taking anticoagulants must ensure they have the knowledge to do so safely and must be aware of their responsibilities as laid out in this document.

**Accountabilities**
Production
Charlotte Carvell, Anticoagulant Specialist Pharmacist

Review and approval
Thrombosis Committee

Ratification
Dr Tim Nokes, Consultant Haematologist & Chair of Thrombosis Committee

Dissemination
Charlotte Carvell, Anticoagulant Specialist Pharmacist

Compliance
Tim Nokes, Consultant Haematologist

**Links to other policies and procedures**
TRW.MMA.POL.265.3 Medicines Management Policy

**Version History**

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>V1</td>
<td>September 2012</td>
<td>Initial Document</td>
</tr>
<tr>
<td>V2</td>
<td>March 2015</td>
<td>Minor amendments and additions made regarding following aspects: 1. Use of novel oral anticoagulant agents (section 8). 2. Typical doses of acenocoumarol and phenindione (section 5.1.2).</td>
</tr>
<tr>
<td>V3</td>
<td>March 2016</td>
<td>Amendments made to wording in sections 5.1.1 and 5.1.2 in consultation with Livewell Southwest in response to Coroner’s report. Terminology update – DOAC replaces NOAC</td>
</tr>
<tr>
<td>V4</td>
<td>July 2018</td>
<td>Additional information in section 8 relating to use of DOACs</td>
</tr>
</tbody>
</table>
Last Approval | Due for Review
---|---
July 2018 | July 2020

PHNT is committed to creating a fully inclusive and accessible service. Making equality and diversity an integral part of the business will enable us to enhance the services we deliver and better meet the needs of patients and staff. We will treat people with dignity and respect, actively promote equality and diversity, and eliminate all forms of discrimination regardless of (but not limited to) age, disability, gender reassignment, race, religion or belief, sex, sexual orientation, marriage/civil partnership and pregnancy/maternity.

An electronic version of this document is available on the Trust Documents Network Share Folder (G:\TrustDocuments). Larger text, Braille and Audio versions can be made available upon request.
# Section Description | Page
---|---
1 | Introduction | 4
2 | Purpose | 4
3 | Definitions | 4
4 | Training and competencies | 4
   4.1 Prescribers | 4
   4.2 DVT clinic staff | 5
   4.3 Nursing staff | 5
   4.4 Pharmacists and pharmacy technicians | 5
5 | Oral anticoagulation | 6
   5.1 Prescriber responsibilities | 6
      5.1.1 Initiation of treatment | 6
      5.1.2 Continuation of prescribing | 7
         5.1.2.1 Drug interactions | 7
      5.1.2.2 Peri-operative management | 8
   5.1.3 Discharge | 8
   5.2 Pharmacist responsibilities | 9
      5.2.1 Clinical screening of inpatient prescriptions | 9
      5.2.2 Dispensing and discharge procedures | 9
   5.3 Nursing responsibilities | 10
      5.3.1 Administration of oral anticoagulants | 10
      5.3.2 Discharge | 10
6 | Intravenous unfractionated heparin | 11
7 | Low molecular weight heparins | 11
8 | Other anticoagulants | 11
9 | Overall responsibility for the document | 12
10 | Consultation and ratification | 12
11 | Dissemination and implementation | 12
12 | Monitoring Compliance and Effectiveness | 12
13 | References | 13

Appendix 1 | Dissemination Plan | 15
Appendix 2 | Review and Approval Checklist | 16
Appendix 3 | Equality Impact Assessment | 17
1 Introduction

The National Patient Safety Agency (NPSA) issued a Safer Practice Notice in March 2007 titled “Actions that can make anticoagulant therapy safer”. It provides guidance for all NHS staff involved in the prescribing, dispensing and administration of oral and parenteral anticoagulants. A joint working group was formed which included representatives from PHNT and PTPCT and local actions agreed for each of the nine action points required by the NPSA alert.

This policy provides guidance for all staff involved in the prescribing, dispensing and administration of oral and parenteral anticoagulants in PHNT to ensure compliance with the NPSA safety notice.

2 Purpose

The purpose of this policy is to provide robust and safe systems to manage the inherent risks to patients from the use of anticoagulant therapy. It meets or exceeds the minimum requirements of the NPSA safer practice notice no.18 with respect to risk assessment, safe procedures, training and audit.

The guidance covers the following key areas:

- Prescribing responsibilities for doctors and non-medical prescribers: initiation, continuation, monitoring and discontinuation of anticoagulant therapy
- Competency of all staff involved with anticoagulant administration or supply
- Safe systems for documenting results and treatment, including effective communication on discharge and the checking by prescribers, pharmacists and nurses that the INR is safe before dispensing or administration
- Promotion of safe practice by re-checking the INR following changes of medication or patient condition
- Providing the patient with appropriate information at commencement of therapy, at discharge from secondary care and throughout the course of treatment
- Standardisation of the strength of intravenous (IV) unfractionated heparin in use.
- Requirement for audit to ensure the guidance is achieving its objectives.

Specific clinical guidance is provided on PHNT Staffnet (see references).

3 Definitions

For the purposes of this policy “oral anticoagulation” is defined as coumarins (warfarin, acenocoumarol) and phenindione. These anticoagulants require monitoring of INR results and dose adjustment according to response. Direct Oral Anticoagulant agents (DOACs) are covered in section 8. Sections of the document that do not specifically mention DOACs are not applicable to these agents.

4 Training and Competencies

4.1 Prescribers

All prescribers that initiate, continue or adjust dosage of anticoagulants must have the necessary work competencies to undertake their work safely.

The competencies are defined by the NPSA (www.nrls.npsa.nhs.uk/resources/type/alerts/)

- Competency no. 1 “Initiating anticoagulant therapy”
• Competency no. 2 "Maintaining oral anticoagulant therapy"
• Competency no. 5 “Preparing and administering heparin therapy”

Practitioners should assess their current level of competence and improve their knowledge and can improve their understanding by completion of the following BMJ e-learning packages (same website as above):
• Starting patients on anticoagulants
• Maintaining patients on anticoagulants.

Anticoagulation is included in the following e-learning packages as part of the medicines management module:
• Doctor’s induction – information about the relevant sections of the drug chart, discharge forms and completion of Yellow Books. Also a strong recommendation to complete the BMJ learning packages and a link to the BMJ learning website.
• Any changes to policy or procedures relating to anticoagulants or any specific problems highlighted by audits or clinical incident reports will be included in the update training medicines management module for prescribers as applicable. Update training modules are reviewed annually.

4.2 DVT Clinic Staff

Registered nurses that work in the DVT clinic administer, supply or adjust dosage of oral anticoagulation, including NOACs, working within a Patient Group Direction (PGD).
Practitioners must have the necessary competency regarding initiation of anticoagulant therapy as above and also NPSA competency no. 4 “Dispensing oral anticoagulants”.

All nursing staff working under this PGD must complete the BMJ e - learning packages and provide a copy of the certificate to their line manager as proof that this has been completed.

4.3 Nursing Staff

Nursing staff who are authorised to administer medications under the Trust Medicines Management Policy may administer anticoagulants.
The medicines management e-learning module completed by new nursing staff includes information about use of the relevant sections of the drug chart.

It is the responsibility of line managers to ensure that staff who administer or discharge patients on anticoagulants have sufficient knowledge to fulfil their responsibilities under this policy. The BMJ e-learning packages (see 4.1) can be used to improve knowledge of anticoagulation.

Nurses who are required to prepare or administer heparin therapy need to have appropriate knowledge of heparin as defined by the NPSA competency no.5 “Preparing and administering heparin therapy” (see section 4.1) and have completed the appropriate Trust IV administration training (see Medicines Management Policy).

4.4 Pharmacists and Pharmacy Technicians

Pharmacists involved in clinically screening prescriptions for anticoagulants and counselling patients should also complete the e-learning packages referred to in 4.1 above.
All pharmacists will be asked to print off the certificates from the BMJ website to show that they have completed the e-learning packages and pharmacists new to the Trust will be required to complete these as part of their departmental induction. Completion will be confirmed by line managers as part of the annual appraisal process.

Pharmacy technicians and preregistration pharmacists may counsel patients on warfarin therapy if they have completed local competency training.
Clinical guidelines to aid prescribing are available on Plymouth Healthnet and in the Plymouth Area Joint Formulary (PAJF). Sections of these guidelines are also reproduced in the inpatient drug prescription and administration record (DPAR).

### 5.1 Prescriber Responsibilities

For inpatients, oral anticoagulants should be prescribed on the “Oral Anticoagulation Prescription & Record Card” section of the DPAR.

All relevant parts of the anticoagulation chart should be completed, including patient details (an addressograph sticker may be used), drug, indication, target INR and intended duration of therapy.

For each dose the date, drug and INR result (if available) need to be completed, as well as the dose and prescriber’s signature. Doses must be prescribed in mg on the DPAR (not the number of tablets to be taken).

Blood for INR tests must be taken in the morning and the result checked and daily dose prescribed before 14.00 where ever possible. Dosing should not be left for the out-of-hours cover team to complete.

To ensure that the anticoagulant doesn’t get overlooked during drug administration rounds the drug should also be written in the regular section of the drug chart with “see anticoagulant prescription” written in the additional information box and the dosage left blank.

#### 5.1.1 Initiation of Treatment

Prescribers should carry out a risk assessment of the benefits versus the risks of therapy for individual patients before starting oral anticoagulation. This should include considerations made regarding choice of agent where DOACs may be an option. The risk assessment should be documented in the patient’s medical notes.

Baseline clotting screen should be performed before starting any anticoagulant and renal function and LFTs should be assessed for patients starting DOACs.

**If oral anticoagulation is to be commenced as an outpatient the patient's GP must be contacted and must agree that they are happy to commence therapy.** This should be for the minority of cases – most patients where a decision to start anticoagulation has been made while an inpatient should commence their therapy while in hospital.

For inpatients indicate that the anticoagulation is newly commenced and write the start date in the relevant place on the DPAR.

The co-prescribing of anti-platelet agents with oral anticoagulants needs very careful safety evaluation as this will significantly increase the risk of bleeding. The indication for anti-platelet therapy and patient risk factors should be assessed for individual patients and decisions on whether anti-platelets are to stop or continue documented in the medical notes. Ensure anti-platelet therapy is crossed off the DPAR if stopped.

When a patient is commenced on an anticoagulant they must receive appropriate verbal information and be provided with a yellow oral anticoagulation pack entitled “Oral Anticoagulant Therapy – Important information for patients” (commonly referred to as a “Yellow Book”).
The information in the Yellow Book should be fully explained to the patient (ward pharmacists will be checking the patient understands this information – see below). The record book should have all relevant sections at the front completed.

Loading regimens are included in the DPAR and clinical guidelines on Plymouth Healthnet. INR tests MUST be performed daily for at least the first four days of treatment. For patients being started on warfarin for stroke prevention in AF or where there are risk factors for bleeding the lower dose loading regimen should be used.

For the initial treatment of deep-vein thrombosis a low molecular weight heparin (enoxaparin) is started at treatment dose (1.5mg/kg) daily together with warfarin. The LMWH needs to be continued for at least 5 days (unless INR > 3) and until the INR >= 2 for 24 hours then stop (see oral anticoagulant guidelines for full details).

5.1.2 Continuation of Prescribing

For existing patients, check that they already have a yellow book and provide a new one if required, ensuring all relevant sections at the front are completed. Sign in the relevant section of the anticoagulant page of the DPAR when this has been done.

Frequent changes in dose should be avoided, although prescribers should beware of other factors which may affect INR and monitor more frequently if necessary (see clinical guidelines).

Prescribers should simplify regimens for patients so that where possible:

- The least number of tablets need to be taken each day
- Constant daily dosing is employed rather than alternating doses

For patients with raised INR, refer to clinical guidelines - INR result, bleeding risk factors or presence of bleeding and risk to patient of reversing anticoagulant therapy should be considered and reversal agents given where indicated. Any serious bleeding associated with anticoagulation must be reported using the Datix incident reporting system.

Any significant change in clinical presentation in a patient on warfarin should trigger an immediate INR test and repeat INRs may be necessary whilst the patient remains unwell. Where patients on DOACs have a significant change in clinical presentation bleeding should be considered and immediate haemoglobin checks carried out. A change in renal function can also result in accumulation of active drug and DOACs may need to be dose reduced or withheld until renal function recovers.

Phenindione and acenocoumarol are rarely used and will only be commenced by a haematology consultant although patients visiting the area may be admitted on either of these agents. Prescribers may therefore be unfamiliar with their usage. Close monitoring of INR is recommended when restarting these agents or adjusting dosage. Acenocoumarol loading doses are usually 6mg then 4mg and maintenance doses between 1-8mg daily. Phenindione loading doses are usually 200mg then 100mg and maintenance doses between 50-150mg daily.

5.1.2.1 Drug Interactions

As so many drugs have a potential, but unpredictable, interaction with oral anticoagulants, ANY change in medication (addition or subtraction) should trigger a repeat INR within 2 - 4 days, with dosage adjustment and further testing as necessary. See Oral Anticoagulation Guidelines for details.

The following drugs that induce Cytochrome P450 liver enzymes may be responsible for an interaction (increased clearance of anticoagulant) that may take up to 2 or 3 weeks to take effect [reference no.4]:

TRW.MMA.POL.637.4 PHNT Anticoagulant Policy
- Barbiturates (including Phenobarbital and Primidone)
- Carbamazepine
- Nevirapine
- Phenytoin
- Rifampicin or Rifabutin
- St Johns Wort

If any of the above drugs are combined with an oral anticoagulant, INR tests should be performed at weekly intervals after any new prescription or change in dose until stabilised. If any of these drugs are reduced in dose or stopped, remember that the INR may rise and this may also take 2 - 3 weeks to become apparent.

5.1.2.2 Peri-operative Management

For elective patients, a decision must be made during the pre-assessment process regarding whether to stop oral anticoagulant and the patient/carer must be provided with written information about when to stop their treatment. Appropriate bridging therapy must be planned, including arrangements for administration if LMWH is prescribed.

For patients who require emergency surgery, consider reversal of anticoagulation, taking into account the risk of delayed surgery and bleeding risks.

Post-operatively all surgical patients should recommence anticoagulation as soon as bleeding risk and absorption of oral medication allow. Appropriate bridging should continue until oral anticoagulant has been reinstated and, for coumarins, target INR reached.

5.1.3 Discharge

The aim should be for most patients to reach a stable INR within target range before discharge.

When a patient on anticoagulants is discharged the prescribing doctor MUST complete the “Oral Anticoagulant Discharge Information" form electronically on e-discharge or on paper if e-discharge is unavailable. This form will be faxed to the patient’s GP by pharmacy.

Completing the discharge form may not remove the need to discuss the patient with the GP or to arrange for INR tests to be taken. Where INR is unstable or not in therapeutic range the GP should be contacted in addition to the form being completed. Use of the acute GP service may be considered for patients with sub-therapeutic INR to allow safe discharge (see clinical guidelines). If you are considering discharging patients for outpatient anticoagulation the referral route for this is via the HOT clinic hosted in the Acute GP Service (AGPS) based on MAU Thrushel. Patients must be assessed as safe for discharge by a senior doctor and be mobile and able to attend on a daily basis.

**Particular care should be taken when discharging a patient close to weekends or public holidays to ensure blood tests can be arranged at an appropriate interval after discharge.**

The patient’s Yellow Book MUST be updated with INR results and doses and the patient made aware of what dose to take and when their next INR test is due.

- For the sake of clarity, the Yellow Book should include the dose as the total in milligrams and not solely as a multiple of tablets e.g. “6 mg (2 x 3 mg tablets) daily”.
- 500 microgram warfarin tablets should be used to prevent the need to halve tablets. Take great care to avoid confusion between 500 microgram and 5 mg on the prescription (avoid the use of the description 0.5 mg).
- Patients will not normally be issued with both 5 mg and 500 microgram tablets.
5.2 Pharmacist Responsibilities

Yellow Books are supplied from Derriford Pharmacy and will be held as ward stock in all areas where they are commonly required. Ward stock supplies will be reordered or topped-up in the same way as stock drugs supplied from pharmacy.

The pharmacist clinically screening a prescription for anticoagulants should consider whether the dose, drug and route are appropriate for the patient. **Any problems, including significant drug interactions will be discussed with the prescriber and appropriate action taken.**

It is the pharmacist clinically checking the prescription for the patient (inpatients, patients being discharged and outpatients) who is responsible for checking that the patient has a current Yellow Book. If the patient does not have an up-to-date book a new one should be supplied and filled out by the pharmacist or by a pre-registration pharmacist or pharmacy technician who has been assessed as competent.

Competent pre-registration pharmacists or pharmacy technicians can counsel patients on anticoagulant therapy (either on the wards or when handing out prescriptions in pharmacy).

5.2.1 Clinical Screening of Inpatient Prescriptions

The ward pharmacist should check the “Oral Anticoagulant Prescription” page of the DPAR has been completed with patient details and information about the anticoagulant therapy. Missing details should be clarified and completed as necessary.

Pharmacists will ensure that the oral anticoagulant is written in the regular section of the DPAR (see 5.1).

It is the ward pharmacist’s responsibility to ensure the information in the Yellow Book has been completed and to keep it up-to-date during the admission. The pharmacist should also check the patient’s understanding of the information in the Yellow Book and give the patient (or carer if applicable) the opportunity to ask questions about their anticoagulant therapy wherever possible. There is a space on the anticoagulation page of the DPAR to indicate when the patient has been counselled.

Ward pharmacists should monitor prescriptions for inpatients taking oral anticoagulants on a daily basis (Monday to Friday) and check whether INR results are available and the dose has been adjusted accordingly. **Any concern about frequency of blood tests or dose should be discussed with the prescriber.**

5.2.2 Dispensing and Discharge Procedures

Patients should be provided with the strengths of oral anticoagulant necessary for them to take their prescribed dose. Pharmacists and medicines management technicians screening prescriptions or ordering supplies should:

- Supply ONLY those strengths required by the patient for the current dose regimen. Order or endorse the prescription with the strengths required. Do not automatically issue 1mg, 3mg and 5mg strengths of warfarin.
- Use 500 microgram tablets when required to prevent patients having to halve tablets, which some patients find is difficult to do and which can lead to inaccuracies in dosage.
- When dispensing, great care should be taken to avoid mix ups between 500 micrograms and 5 mg tablets. Individual patients should NOT usually be issued with both of these strengths.
- Dispensing labels should state “take as directed” and should not include a specific dose.
For discharge prescriptions the screening pharmacist MUST check that an “Oral Anticoagulant Discharge Form” has been completed by the prescriber and check the information on this form is up-to-date, complete and consistent with the information available from other sources (e.g. Yellow Book, DPAR). The prescriber should be contacted if necessary to resolve any queries. Amendments to the form should be made if required.

A copy of the Discharge Form and the anticoagulant prescription page of the DPAR will be faxed to the patient’s GP surgery and copies retained in pharmacy.

If the pharmacist clinically screening the prescription has access to the Yellow Book (or has issued a new one) at the point of screening the pharmacist should ensure that all details in the front of the book, INR results and doses are filled out.

Oral anticoagulants will not usually be dispensed into compliance aids.

5.3 Nursing Responsibilities

Oral anticoagulants should be administered on the 2 p.m. drug administration round whilst the patient is an inpatient. This is to ensure that warfarin dosing is decided by the medical team looking after the patient and not left for the night cover to complete. If the dose is not prescribed by this time the medical team should be contacted in the afternoon to prescribe the dose as soon as possible. After discharge the patient can take their dose in the evenings at around 6 p.m.

5.3.1 Administration of Oral Anticoagulants

Before administering warfarin or any other oral anticoagulant to a patient, the nurse should check:

- The patient’s identity as per Medicines Management Policy
- The dose to be given for that day has been completed by the doctor on the anticoagulation page of the DPAR
- The dose to be given for that day has not already been administered
- A recent INR test has been performed and the result is either within target or the doctor has adjusted the dose if the INR is outside of target – INR test should be performed more frequently if patient is acutely unwell and within 2 - 4 days of any change in other medication

The nurse administering the dose should complete the dose given, the time given and their initials on the anticoagulant dose chart.

If the nurse is concerned about the dose or frequency of blood tests this should be discussed with the prescribing doctor.

5.3.2 Discharge

If a pharmacist or doctor has not already done so, the nurse must ensure that the records in the yellow book are up-to-date and complete when the patient is discharged.

The nurse issuing the discharge medication to the patient must check that the current dose and when this dose is due to be taken has been communicated to the patient or carer. The nurse should also confirm that the patient has understood the information in the yellow book or ensure relevant information is passed on to the patient’s carers. The yellow book must be sent with the patient at discharge.
6 Intravenous Unfractionated Heparin

Where an infusion of unfractionated heparin is required the use of a standard ready-to-use 1000 units/ml preparation is mandatory. Changes in dose (usually based on APTT ratio) should be made by adjusting the rate of administration. Monitoring for heparin induced thrombocytopenia should also be carried out (see clinical guidelines).

A specific infusion chart is available within PHNT and must be used to prescribe and record administration and dose adjustment for intravenous heparin infusions.

Specialist areas e.g. haemodialysis, critical care areas, cardiothoracic theatres should only use standard 1000 units/ml products and base any specialist protocols in use in these areas on this concentration of heparin. The need for dilution prior to administration should be avoided wherever possible.

No other strengths of intravenous unfractionated heparin will be stocked on wards, except line flushes which must only be held by limited areas in agreement with a senior pharmacist.

7 Low Molecular Weight Heparins

Prescribed doses of low molecular weight heparins (LMWHs) for the treatment of a thromboembolic event are dependent on the weight of the patient and renal function.

- A patient’s weight MUST be used as the basis for calculating the required treatment dose of LMWH. The weight must be accurately recorded in kilograms (kg) on the front of the DPAR (when in use) and in the medical notes.
- Patients should be weighed and their renal function checked at the start of therapy and, where applicable, during treatment.
- If this information is unavailable do not delay the first dose, but ensure these parameters are checked as soon as possible and the next dose adjusted accordingly.

Clinical guidelines are available on Staffnet which include advice on dosage and monitoring.

Essential information such as dose, weight, renal function, indication and duration of treatment must be communicated at transfers of care.

Patients discharged on LMWH should be encouraged to self-administer if possible and can be taught how to do this by a nurse. If a District Nurse is required to administer the injection the ward nurse will make arrangements with the appropriate community team and the prescriber must complete a blue community prescription card.

All patients discharged on LMWH must be supplied with a sharps bin.

8 Other Anticoagulants

A number of novel oral anticoagulant agents have been licensed for indications including prevention of VTE after orthopaedic surgery, stroke prevention in patients with AF and DVT treatment or prevention. These agents are direct thrombin inhibitors (e.g. dabigatran) or inhibitors of factor Xa (e.g. rivaroxaban, apixaban). There are also likely to be more new agents available in the future. INR monitoring is not required with these drugs.

These agents should only be used at licensed doses, for licensed indications and where NICE have made a positive recommendation for the use.

When considering initiating an anticoagulant or choosing between agents a risk assessment should be carried out. Factors to consider include:

TRW.MMA.POL.637.4 PHNT Anticoagulant Policy
• Renal function,
• Risk factors for serious bleeding – there is no specific antidote to direct factor Xa inhibitors in the event of haemorrhage,
• Interacting medications – e.g. dabigatran is contraindicated with certain medications and requires dose adjustment with others,
• Previous anticoagulant use and whether INR has been well controlled,
• An informed discussion of risks and benefits should take place with the patient before any anticoagulant therapy is initiated.

Where initial treatment dose differs from maintenance dose duration of initial regimen and continuing dosage must be clearly stated on prescription and discharge letters.

Patients on DOACs must be provided with a completed “yellow card” to carry. Cards are available separately from the “yellow book” packs for this purpose.

Guidelines regarding VTE prophylaxis following orthopaedic surgery, choice of agent for stroke prevention in AF and use of rivaroxaban for VTE are available on Staffnet. Further clinical guidelines must be produced for other indications prior to local approval being given and made available on Staffnet.

There is no specific antidote available to any of these agents. Clinical guidelines regarding management of anticoagulation during the peri-operative period and actions to take in the event of major bleeding are available on Staffnet.

Other anticoagulants may be used within the Trust for specified indications or in particular circumstances. For example, fondaparinux is used for patients with acute coronary syndromes or danaparoid and argatroban are available for when a patient has HIT diagnosed. Local clinical guidelines and product information should be consulted to ensure these anticoagulants are used safely.

Where a patient is prescribed one of these anticoagulants care must be taken that anticoagulant therapy is not unintentionally duplicated. It is NOT necessary to overlap treatment with LMWH and DOACs for example. Care should also be taken when switching a patient between anticoagulants and advice sought from haematology or pharmacy if appropriate.

All anticoagulants must be prescribed on the DPAR for inpatients. The discharge letter must state indication and duration for all newly initiated anticoagulants.

9 Overall Responsibility for the Document

Overall responsibility for this document lies with Dr Tim Nokes, Consultant Haematologist.

10 Consultation and Ratification

This Policy has been written by Charlotte Carvell, Anticoagulant Specialist Pharmacist, in consultation with Tim Nokes, Consultant Haematologist. The policy has been reviewed and ratified by the Thrombosis Committee and the Medicines Governance Committee.

11 Dissemination and Implementation

• Following approval and ratification by the Thrombosis Committee this policy will be rolled out across the Trust.
• Publication of this Policy will be publicised in Vital signs and in the weekly staff news brief. The Policy will be sent to all ward managers, doctors, DVT clinic staff, Pharmacists and...
PHNT Anticoagulant Policy

Pharmacy technicians, and a copy will be made available on the Trust-wide Shared Drive called Trust Document Drive

12 Monitoring Compliance and Effectiveness

Every 2 years the following parameters from the NPSA audit checklist (“Audit of safety indicators”) will be audited retrospectively over a period of one month using the information on the faxed discharge forms and DPAR copies held in pharmacy and INR results from the iLab system:

For all patients starting on oral anticoagulants
- % patients developing INR > 5.0
- % patients following loading protocol
- % patients with therapeutic INR at discharge
- % patients not issued with patient-held written information pack (yellow book)
- % patients discharged without a date for next INR test
- % patients with unknown diagnosis, target INR or duration
- % patients with inappropriate target INR for diagnosis

For patients established on oral anticoagulants before admission
- % patients developing INR > 5.0 and those developing INR > 8.0
- % INR results > 1.0 below target range (e.g. INR < 1.5 if target 2.5)
- % INR results within target range
- % patients with unknown diagnosis, target INR or duration
- % patients with inappropriate target INR for diagnosis
- % patients without patient-held written information (yellow book)
- % patients discharged without a date for next INR test

Every 12 months there will also be a review of patient safety incident data (drawn from Datix) involving anticoagulants over the preceding 12 months. This data will be reviewed for common themes. Data will also include any reported incidents relating to bleeding associated with anticoagulants.

These audits will be reported back to the Medicines Governance and Thrombosis Committees.

Audit of safety indicators and clinical incidents will also take place in primary-care and learning points from both primary and secondary care shared via the joint anticoagulation working group. The working group, with representatives from primary and secondary care, will continue to meet when necessary to ensure compliance with NPSA patient safety alert 18 and to discuss any issues across the interface.

Training: Individual training is monitored through the HR personnel and training records.

13 References

1. National Patient Safety Agency (NPSA) Safer Practice Notice no. 18 (Mar 2007) “Actions that can make anticoagulant therapy safer”
2. Plymouth Area Joint Formulary www.plymouthformulary.nhs.uk
3. BNF (Current Edition)

9. Local clinical guidelines on Plymouth Heathnet (November 2014):
   - Adult oral anticoagulation guidelines
   - DVT guidelines
   - PE treatment guideline
   - Suspected PE in pregnancy
   - LMWHs in secondary care
   - Guidelines for the use of LMWHs in primary care
   - Guideline for intravenous unfractionated heparin administration
   - HIT Guidelines
   - Unstable coronary artery syndromes
   - Peri-operative management of warfarin (contained in Pre-operative assessment guidelines)
   - Peninsula Heart & Stroke Network Guidance: Dabigatran & Rivaroxaban for the prevention of stroke and systemic embolism in AF
   - Peninsula Heart & Stroke Network Factsheet: Rivaroxaban for treatment and prevention of DVTs
   - Treatment of severe bleeding in patients on DOACs
## Dissemination Plan

### Core Information

<table>
<thead>
<tr>
<th>Document Title</th>
<th>Anticoagulation: Safe prescribing, dispensing and administration of oral and parenteral anticoagulants</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date Finalised</td>
<td>March 2015</td>
</tr>
<tr>
<td>Dissemination Lead</td>
<td>Charlotte Carvell, Anticoagulant Specialist Pharmacist</td>
</tr>
</tbody>
</table>

### Previous Documents

<table>
<thead>
<tr>
<th>Previous document in use?</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action to retrieve old copies.</td>
<td>Document to be replaced on intranet by new version. No authorised paper versions in use.</td>
</tr>
</tbody>
</table>

### Dissemination Plan

<table>
<thead>
<tr>
<th>Recipient(s)</th>
<th>When</th>
<th>How</th>
<th>Responsibility</th>
<th>Progress update</th>
</tr>
</thead>
<tbody>
<tr>
<td>All ward managers</td>
<td>March 2016</td>
<td>Vital signs</td>
<td>Charlotte Carvell</td>
<td></td>
</tr>
<tr>
<td>All DVT clinic staff</td>
<td>March 2016</td>
<td>Vital signs</td>
<td>Charlotte Carvell</td>
<td></td>
</tr>
<tr>
<td>All doctors</td>
<td>March 2015</td>
<td>Vital signs</td>
<td>Charlotte Carvell</td>
<td></td>
</tr>
<tr>
<td>All Pharmacists and Pharmacy technicians</td>
<td>March 2015</td>
<td>Vital signs and e-mail</td>
<td>Charlotte Carvell</td>
<td></td>
</tr>
<tr>
<td>Review</td>
<td>Y</td>
<td>N</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------------------------------------------</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Review</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Title</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the title clear and unambiguous?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is it clear whether the document is a policy, procedure, protocol, framework, APN or SOP?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the style &amp; format comply?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Rationale</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are reasons for development of the document stated?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Development Process</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the method described in brief?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are people involved in the development identified?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Has a reasonable attempt has been made to ensure relevant expertise has been used?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is there evidence of consultation with stakeholders and users?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Content</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the objective of the document clear?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the target population clear and unambiguous?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are the intended outcomes described?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are the statements clear and unambiguous?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Evidence Base</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the type of evidence to support the document identified explicitly?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are key references cited and in full?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are supporting documents referenced?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Approval</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the document identify which committee/group will review it?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If appropriate have the joint Human Resources/staff side committee (or equivalent) approved the document?</td>
<td>NA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the document identify which Executive Director will ratify it?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dissemination &amp; Implementation</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is there an outline/plan to identify how this will be done?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the plan include the necessary training/support to ensure compliance?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Document Control</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Does the document identify where it will be held?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Have archiving arrangements for superseded documents been addressed?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Monitoring Compliance &amp; Effectiveness</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are there measurable standards or KPIs to support the monitoring of compliance with and effectiveness of the document?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is there a plan to review or audit compliance with the document?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Review Date</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the review date identified?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the frequency of review identified? If so is it acceptable?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Overall Responsibility</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is it clear who will be responsible for co-ordinating the dissemination, implementation and review of the document?</td>
<td>Y</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Anticoagulant Policy

**Manager:** Andrew Prowse  
**Directorate:** Pharmacy  
**Date:** 12.09.2012 (reviewed by C. Carvell July 2018 – no changes)  

**Title:** Anticoagulation: Safe prescribing, dispensing and administration of oral and parenteral anticoagulants

**What are the aims, objectives & projected outcomes?**  
The purpose of this policy is to provide robust and safe systems to manage the inherent risks to patients from the use of anticoagulant therapy. It meets or exceeds the minimum requirements of the NPSA safer practice notice no.18 with respect to risk assessment, safe procedures, training and audit.

## Scope of the assessment

See names and contributors on page one of the policy

## Collecting data

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race</td>
<td>There is no evidence to suggest that there is a disproportionate impact on race regarding this policy</td>
</tr>
<tr>
<td>Religion</td>
<td>There is no evidence to suggest that there is a disproportionate impact on religion or belief and non-belief regarding this policy</td>
</tr>
<tr>
<td>Disability</td>
<td>There is no evidence to suggest that there is a disproportionate impact on disability regarding this policy</td>
</tr>
<tr>
<td>Sex</td>
<td>There is no evidence to suggest that there is a disproportionate impact on gender regarding this policy</td>
</tr>
<tr>
<td>Gender Identity</td>
<td>There is no evidence to suggest that there is a disproportionate impact on gender identity regarding this policy</td>
</tr>
<tr>
<td>Sexual Orientation</td>
<td>There is no evidence to suggest that there is a disproportionate impact on sexual orientation regarding this policy</td>
</tr>
<tr>
<td>Age</td>
<td>There is no evidence to suggest that there is a disproportionate impact on age regarding this policy</td>
</tr>
<tr>
<td>Socio-Economic</td>
<td>There is no evidence to suggest that there is a disproportionate impact on socio-economic issues regarding this policy</td>
</tr>
<tr>
<td>Human Rights</td>
<td>There is no evidence to suggest that there is a disproportionate impact on human rights regarding this policy</td>
</tr>
</tbody>
</table>

**What are the overall trends/patterns in the above data?**  
Overall patterns and trend are not identified.

**Specific issues and data gaps that may need to be addressed through consultation or further research**  
There are no specific equality & human rights issues and data gaps that need to be addressed through consultation and/or further research

## Involving and consulting stakeholders

**Internal involvement and consultation**  
Thrombosis Committee

**External involvement and consultation**  
There has been no external consultation or involvement

---

TRW.MMA.POL.637.4 PHNT Anticoagulant Policy
This policy has no impact on equality

<table>
<thead>
<tr>
<th>Action Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

TRW.MMA.POL.637.4 PHNT Anticoagulant Policy